A single dose of intravenous iron dextran did not improve clinical outcomes in acute kidney injury patients with iron deficiency, specifically evaluated by MAKE90.
The treatment was found to be safe, offering no significant risks despite the lack of outcome improvement.
Assessment focused on hemoglobin values, showing no detectable benefits from the iron supplementation compared to usual care.
Highlighting the importance of further investigation into the effects of intravenous iron in kidney injury contexts.
Abstract
In patients with AKI and iron deficiency, a single dose of IV iron, compared to usual care, did not improve clinical outcomes evaluated by MAKE90, the hemoglobin value, but was safe.
Ask AI
Helpful
Bookmark
Share
View Full Paper
Cite This Study
Chávez-Iñiguez et al. (2026) studied this question.